0J2O.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0J2O.L in your mock portfolio yet.
A PE ratio of 22.85 on EPS of 3.00 implies the market is valuing Halozyme as a profitable, established biotech rather than a speculative pre‑revenue name. The valuation multiple is moderate for the sector, suggesting investors expect continued earnings stability or moderate growth rather than hyper‑growth. Overall, the profitability profile looks supportive of the current share price level.
The stock trades at $68.53, down 6.3% over the last month, but remains far above its 200‑day moving average of $37.43, signaling a strong longer‑term uptrend. An RSI of 62.11 is elevated but not yet overbought, suggesting momentum is positive but could be vulnerable to near‑term consolidation. Overall, technicals lean constructive over the medium term but are not at an ideal low‑risk entry point.
Website traffic is flat at a relatively low level, offering little sign of accelerating external engagement. Job openings have fallen 26.3% month over month to 14, which can indicate cost discipline but also potentially slower growth or reduced expansion plans. Social media presence is modest and growing only slowly, suggesting limited incremental retail or brand‑driven investor interest.
Halozyme Therapeutics appears fundamentally sound and profitable, with a valuation that is supportive but not deeply discounted and a price trend that remains firmly above long‑term support despite a recent pullback. However, alternative data signals—flat web traffic, reduced hiring, and modest social media growth—do not point to a strong near‑term acceleration story. Taken together, the setup looks balanced: constructive fundamentals and technicals offset by softer growth signals from alternative data.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: